- Home
- ZH vs AMRN Comparison
ZH vs AMRN Comparison
Compare ZH & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.22
HOLD
Current Price
$13.99
Company Overview
Basic Information| Metric | ZH | AMRN |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.3M | 339.8M |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ZH | AMRN |
|---|---|---|
| Price | $3.22 | $13.99 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 299.6K | 81.8K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $3.23 | $0.35 |
| 52 Week High | $5.87 | $20.90 |
Technical Indicators
Market Signals| Indicator | ZH | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 37.58 |
| Support Level | N/A | $13.15 |
| Resistance Level | $4.20 | $14.55 |
| Average True Range (ATR) | 0.14 | 0.70 |
| MACD | -0.03 | -0.18 |
| Stochastic Oscillator | 1.75 | 11.24 |
Price Performance
Historical Comparison ZH
AMRN
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.